These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22204524)

  • 21. [Value of the theory of the optimal sampling scheme for bioequivalence studies].
    Tod M; Petitjean O; Nicolas P
    Therapie; 1993; 48(1):7-13. PubMed ID: 8356559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimum experimental designs for properties of a compartmental model.
    Atkinson AC; Chaloner K; Herzberg AM; Juritz J
    Biometrics; 1993 Jun; 49(2):325-37. PubMed ID: 8369370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An empirical multivariate log-normal distribution representing uncertainty of biokinetic parameters for 137Cs.
    Miller G; Melo D; Martz H; Bertelli L
    Radiat Prot Dosimetry; 2008; 131(2):198-211. PubMed ID: 18420573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gamma generalized linear models for pharmacokinetic data.
    Salway R; Wakefield J
    Biometrics; 2008 Jun; 64(2):620-6. PubMed ID: 17888039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Monte Carlo method for calculating Bayesian uncertainties in internal dosimetry.
    Puncher M; Birchall A
    Radiat Prot Dosimetry; 2008; 132(1):1-12. PubMed ID: 18806256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Robust designs in longitudinal studies accounting for parameter and model uncertainties - application to count data.
    Loingeville F; Nguyen TT; Riviere MK; Mentré F
    J Biopharm Stat; 2020; 30(1):31-45. PubMed ID: 31032703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition.
    Nong A; Tan YM; Krolski ME; Wang J; Lunchick C; Conolly RB; Clewell HJ
    J Toxicol Environ Health A; 2008; 71(20):1363-81. PubMed ID: 18704829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model.
    Merlé Y; Mentré F
    J Pharmacokinet Biopharm; 1995 Feb; 23(1):101-25. PubMed ID: 8576840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Limited sampling strategies to estimate exposure to the green tea polyphenol, epigallocatechin gallate, in fasting and fed conditions.
    Foster DR; Sowinski KM; Chow HH; Overholser BR
    Ther Drug Monit; 2007 Dec; 29(6):835-42. PubMed ID: 18043484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statistical analysis of chemical transformation kinetics using Markov-Chain Monte Carlo methods.
    Görlitz L; Gao Z; Schmitt W
    Environ Sci Technol; 2011 May; 45(10):4429-37. PubMed ID: 21526818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models.
    Vrijens B; Tousset E; Rode R; Bertz R; Mayer S; Urquhart J
    J Clin Pharmacol; 2005 Apr; 45(4):461-7. PubMed ID: 15778427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.
    Yang S; Roger J
    Pharm Stat; 2010; 9(4):313-30. PubMed ID: 20043295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Markov Chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age.
    Allen BC; Hack CE; Clewell HJ
    Risk Anal; 2007 Aug; 27(4):947-59. PubMed ID: 17958503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Robust and Fast Markov Chain Monte Carlo Sampling of Diffusion MRI Microstructure Models.
    Harms RL; Roebroeck A
    Front Neuroinform; 2018; 12():97. PubMed ID: 30618702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria.
    Tod M; Rocchisani JM
    Comput Methods Programs Biomed; 1996 Jun; 50(1):13-22. PubMed ID: 8835836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.
    D'Argenio DZ
    Math Biosci; 1990 Apr; 99(1):105-18. PubMed ID: 2134510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal Bayesian Adaptive Design for Test-Item Calibration.
    van der Linden WJ; Ren H
    Psychometrika; 2015 Jun; 80(2):263-88. PubMed ID: 24407735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective evaluation of a D-optimal designed population pharmacokinetic study.
    Green B; Duffull SB
    J Pharmacokinet Pharmacodyn; 2003 Apr; 30(2):145-61. PubMed ID: 12942685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.